Product Description
MINT91 is a small molecule drug developed in-house by Chugai for solid tumors. (Sourced from: https://www.chugai-pharm.co.jp/english/ir/product/pipeline.html)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company Founding Year: 1896
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2031240713 |
jRCT2031240713 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2028-06-30 |
Recent News Events
Date |
Type |
Title |
|---|